High-tissue FRMD6 expression predicts better outcomes among colorectal cancer patients

Arthur vonKoskull,Jaana Hagström,Caj Haglund,Tuomas Kaprio,Camilla Böckelman
DOI: https://doi.org/10.1080/1354750x.2024.2321916
2024-03-02
Biomarkers
Abstract:Introduction Colorectal cancer (CRC) is the second most common cause of cancer-related deaths. The hippo pathway works as a regulator of organ growth and is often a target for mutations in cancer. Ferm domain containing protein 6 (FRMD6) is an activator of the hippo pathway. This study aimed to explore the role of FRMD6 in CRC and to determine how well it works as a prognostic factor among CRC patients.
biotechnology & applied microbiology,toxicology
What problem does this paper attempt to address?